MicroRNAs as Potential Therapeutic Targets for Pancreatic Cancer

Pancreatic cancer is one of the most deadly cancers worldwide. According to the American Cancer Society, it has a 5-year survival rate of just 12%—a statistic that hasn’t improved much in decades. The biggest challenges? It’s often diagnosed too late, resists standard chemotherapy, and spreads quickly. But new research suggests tiny molecules called microRNAs (miRNAs) could hold the key to better treatments.

Xiangyu Chu, Dan Wei, and colleagues from the Department of General Surgery at Peking University First Hospital recently reviewed how miRNAs work in pancreatic cancer and their potential as targeted therapies. Their findings, published in the Chinese Medical Journal, offer hope for a disease that’s long frustrated doctors and patients.

What Are MicroRNAs?

MiRNAs are short, non-coding bits of RNA—molecules that help regulate gene activity. Unlike messenger RNA (mRNA), which carries instructions for making proteins, miRNAs act like “gene volume knobs.” They bind to the 3’ untranslated region (UTR) of target mRNAs, either slowing protein production or marking the mRNA for destruction.

Nearly 60% of human genes are regulated by miRNAs. When they’re working normally, they keep cell growth, division, and death in balance. But in cancer, this balance breaks down: some miRNAs are too low (tumor suppressors that would slow cancer) while others are too high (oncogenic miRNAs that fuel growth).

MiRNAs in Pancreatic Cancer: Tumor Suppressors vs. Oncogenes

The research highlights two key types of miRNAs in pancreatic cancer:

1. Tumor Suppressor MiRNAs

These miRNAs act as “brakes” on cancer. When their levels drop, cancer cells grow unchecked. Restoring them can slow tumor progression, promote cell death (apoptosis), and make cancer more sensitive to chemotherapy.

For example:

miR-145: Targets multiple genes (like TGF-β receptor, MUC13, and NEDD9) to stop pancreatic cancer cells from multiplying, moving, or invading other tissues. It also makes cells more sensitive to gemcitabine—the standard first-line chemo drug.
miR-34: Blocks pathways like Wnt/β-catenin and Notch to induce apoptosis and reduce metastasis. It also targets the “Slug” gene, which helps cancer cells resist gemcitabine.
miR-205: Inhibits cancer stem cells (the “root” of tumors) and boosts sensitivity to chemo.

2. Oncogenic MiRNAs

These miRNAs act as “gas pedals” for cancer. They turn off tumor suppressor genes and activate pathways that drive growth, invasion, and drug resistance.

The most well-studied oncogenic miRNA in pancreatic cancer is miR-21. It:

Promotes cell division by targeting genes like PTEN and PDCD4.
Makes cells resistant to 5-fluorouracil (another chemo drug).
Creates a “positive feedback loop” with the EGF signaling pathway—EGF increases miR-21, which in turn makes EGF more active, fueling endless growth.

Other problematic miRNAs include miR-155 (which activates STAT3 to drive proliferation) and miR-210 (which spreads drug resistance through exosomes—tiny cell-derived vesicles).

The Big Challenge: Delivering MiRNAs to Cancer Cells

MiRNAs are powerful, but they have a major limitation: they’re too fragile to survive in the body on their own. They’re quickly broken down by enzymes or cleared by the kidneys, and their negative charge repels cell membranes.

To fix this, researchers are testing delivery systems to get miRNAs where they need to go:

Viral Vectors

Modified viruses (like lentiviruses or adenoviruses) can carry miRNAs into cells. They’re efficient but risky—they can cause immune reactions or insert themselves into DNA, potentially triggering mutations.

Nanoparticles & Liposomes

Non-viral carriers like lipid nanoparticles (LNPs) or albumin-coated liposomes are safer. They protect miRNAs from degradation and can be “targeted” to cancer cells using molecules like iRGD (which binds to tumor blood vessels). For example:

iRGD-TPN-21: Delivers anti-miR-21 to tumors, slowing growth in mice.
Liposome-miR-216b: Reduces KRAS (a key cancer gene) by 70% in lab cells.

Exosomes

These are natural vesicles released by cells. They’re less likely to trigger immune reactions and can carry miRNAs directly to cancer cells. Studies show exosomes loaded with miR-145 or miR-34a can slow pancreatic cancer growth in mice.

Combination Therapies: MiRNAs + Chemo or Targeted Drugs

Pancreatic cancer is complex—no single miRNA will “cure” it. That’s why researchers are testing combination therapies to hit cancer from multiple angles:

miR-345 + Gemcitabine: A dual-delivery nanoparticle releases both molecules, stopping tumor growth and metastasis better than either alone.
miR-205 + Cetuximab: Cetuximab (an EGFR-targeting antibody) guides a micelle loaded with miR-205 and gemcitabine to cancer cells. It reverses gemcitabine resistance in advanced tumors.
miR-let7b + GDC-0449: This combo targets both cancer cells (let7b) and the tumor microenvironment (GDC-0449, a Hedgehog pathway inhibitor). It’s stable in serum and releases drugs slowly.

Clinical Trials: From Lab to Patients

The first miRNA-based therapies are now in human trials—with mixed results:

MRX34 (Liposomal miR-34a)

This was the first phase I trial of a miRNA mimic for solid tumors. Forty-seven patients (including 5 with pancreatic cancer) received twice-weekly infusions. While 16 had stable disease and 3 had partial responses, the trial was halted early after 4 patients died from severe immune reactions.

siG12D-LODER + Gemcitabine

For inoperable pancreatic cancer, researchers tested a tiny implant that releases siRNA (a cousin of miRNA) targeting the KRAS(G12D) mutation—found in 90% of pancreatic cancers. Combined with gemcitabine, 10 of 12 patients had stable disease, and 2 had partial responses. Side effects were mild (abdominal pain, nausea).

The Road Ahead: Promise and Challenges

MiRNAs offer a precision medicine approach to pancreatic cancer—targeting the specific genes driving your tumor, not just all dividing cells. But there’s still work to do:

Better Delivery: Carriers need to be more efficient, less toxic, and better at targeting tumors.
Personalization: MiRNA profiles vary by patient—we need tests to find which miRNAs to target.
Safety: Avoiding immune reactions (like those in the MRX34 trial) is critical.
Understanding Off-Target Effects: MiRNAs regulate multiple genes—we need to make sure they don’t harm healthy cells.

Conclusion

Pancreatic cancer is tough, but miRNAs are changing the game. From lab studies showing they can slow tumor growth to clinical trials with promising (if cautious) results, these tiny molecules are proving they’re more than just “biological curiosity.”

As Chu and colleagues write: “Further understanding of miRNA mechanisms and optimized delivery systems will unlock their potential as a new class of pancreatic cancer therapies.” For patients and doctors alike, that’s a reason to hope.

Xiangyu Chu, Dan Wei, Xinxin Liu, Di Long, Xiaodong Tian, Yinmo Yang. MicroRNAs as Potential Therapeutic Targets for Pancreatic Cancer: Recent Progress and Future Prospects. Chinese Medical Journal. 2022;135(1):4–10. doi: doi.org/10.1097/CM9.0000000000001826

Was this helpful?

0 / 0